Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Recordati Industria Chimica e Farmaceutica SPA ( (IT:REC) ) has issued an update.
Recordati S.p.A. announced the resignation of Dr. Luigi La Corte from his role as Group CFO, effective at the end of the year, while he will continue to serve on the Board of Directors. The company is considering both internal and external candidates for the CFO position and will announce a successor in due course. The resignation is accompanied by a financial package and retention of certain stock options for Dr. La Corte. Additionally, the Board confirmed the independence of Dr. Silvia Mina as a Statutory Auditor, following the resignation of Dr. Livia Amidani Aliberti.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR57.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
More about Recordati Industria Chimica e Farmaceutica SPA
Recordati is an international pharmaceutical group listed on the Italian Stock Exchange. Originating from a family-run pharmacy in Northern Italy in the 1920s, the company now provides therapeutic options in both general and specialist medicine, as well as for rare diseases. Recordati operates in a fully integrated manner, covering clinical development, production, marketing, and licensing of active ingredients and finished products. The company is present in about 150 countries across the EMEA, Americas, and APAC regions, employing over 4,500 people worldwide.
Average Trading Volume: 232,205
Technical Sentiment Signal: Buy
Current Market Cap: €10.89B
For detailed information about REC stock, go to TipRanks’ Stock Analysis page.